Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Terminated 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 46Breast 8Thoracic 7Head & Neck 7Gastrointestinal 6Gynecologic 5Dermatologic 4Sarcoma 3Lymphoid 2Other solid neoplasm 1Myeloid 1Classical hematology 1CNS 1

Conditions

Brain Neoplasms 637Glioblastoma 567Glioma 404Neuroblastoma 174Neoplasms 125Astrocytoma 107Central Nervous System Neoplasms 105Medulloblastoma 89Breast Neoplasms 86Meningioma 85Melanoma 76Carcinoma, Non-Small-Cell Lung 76Lung Neoplasms 69Sarcoma 65Ependymoma 63Neurofibromatosis 1 61Recurrence 50Neoplasm Metastasis 48Oligodendroglioma 47Meningeal Carcinomatosis 47Osteosarcoma 46Diffuse Intrinsic Pontine Glioma 45Rhabdomyosarcoma 44Pheochromocytoma 44Paraganglioma 42Rhabdoid Tumor 41Gliosarcoma 40Pancreatic Neoplasms 39Sarcoma, Ewing 38Ovarian Neoplasms 32

Interventions

temsirolimus 1Valproic Acid 1Sirolimus 1Immunoglobulin G 1Disulfides 1Cetuximab 1Bevacizumab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Urologic Neoplasms × CNS × 1 year × Clear all
NCT01552434 2026-05-15

Bevacizumab and Temsirolimus Alone or in Combination With Valproic Acid or Cetuximab in Treating Patients With Advanced or Metastatic Malignancy or Other Benign Disease

M.D. Anderson Cancer Center

Phase 1 Terminated
154 enrolled
BreastCNSGenitourinaryHead & NeckLymphoidMyeloidSarcoma

Breast Neoplasms, Carcinoma, Transitional Cell, Endocrine Gland Neoplasms, Castleman Disease, Mouth Neoplasms, Neoplasm Metastasis, Neoplasms, Pharyngeal Neoplasms, Recurrence, Sarcoma, Soft Tissue Neoplasms, Thyroid Neoplasms, Urologic Neoplasms, Neurofibromatosis 2, Lymphangioleiomyomatosis, Neoplasms, Mesothelial, Erdheim-Chester Disease

Data powered by HemOnc (CC BY 4.0) Colophon âš¡